BrainStorm Cell Therapeutics Inc (BCLI)

[tedpeele]

Remarkable:

From recent interview:

BN: Let's talk about the response rate in the Phase 2 trial, or more specifically, the responder analysis. There was obviously a great response immediately after transplantation. The data show a 74% response rate for week 2 and a 54% response rate after week 4. In both of these instances, the improvement equated to a 100% improvement in slope (ALSFRS-R score) compared to pre-treatment. First question; are these types of stark improvements common in ALS patients?

MC: No, not at all. I've been treating patients with ALS for over 25 years and we very rarely see instances of 100% improvement. Patients will ebb and flow and the disease has periods of stabilization and then rapid decline, but improvement is very rare in ALS. The trajectory is almost always downhill. We do not see this type of response on riluzole.